Academic title (Akademischer Titel):
Prof. Dr. med.

Date of birth (Geburtsdatum): 
July 20th 1958

Nationality (Nationalität):
German

Present position (Gegenwärtige Position):
Assistant Medical Director, Clinic for Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf / Germany (since: 01/1997)

Professional qualifications (Berufliche Qualifikation mit Angabe von erworbenem Grad, Datum und Universität):

1989
Academic Title “Dr. med.”
Faculty of Medicine, University of Hamburg, Germany

01/1995
Board certified “Internal Medicine"    

10/1995
Exam of the European Society for Medical Oncology (ESMO)

03/1997
Board certified "Haematology and Medical Oncology"

12/2000
Final Habilitation Procedure
Faculty of Medicine, University of Hamburg, Germany

05/2001
Qualification "Venia legendi" for the subject "Internal Medicine"    

06/2006
Professor of Medicine
Faculty of Medicine, University of Hamburg, Germany

09/2006
Chair
EBMT, MDS Subcommittee

Previous appointments (Frühere Positionen):

1982 – 1988
Study of Human Medicine
Faculty of Medicine, University of Hamburg, Germany

04/1988
Observer
MD Anderson Hospital in Houston/Texas, USA

1988 – 1992
Fellowship/Resident Internal Medicine
Israelitic Hospital, Hamburg, Germany
(Director: Prof. Dr. H. Frenzel)

1993 – 1996
Scientific Assistant/Resident 
Dept. of Oncology and Haematology, Clinic and Policlinic of Internal Medicine, University Hospital Hamburg, Germany
(Director: Prof. Dr. D. K. Hossfeld)

Since 01/1997
Assistant Medical Director
Centre of Bone Marrow Transplantation
Clinic and Policlinic of Internal Medicine
University Hospital Hamburg, Germany
(Director: Prof.. Dr. A. R. Zander)

Membership of medical scientific societies (Mitgliedschaft in medizinisch-wissenschaftlichen Gesellschaften):

• Deutsche Krebsgesellschaft
• Arbeitsgemeinschaft für internistische Onkologie
• Hamburger Krebsgesellschaft
• European Society of Medical Oncology
• American Society of Clinical Oncology
• Bund Deutscher Internisten
• European Group for Blood and Marrow Transplantation
• Deutsche Arbeitsgemeinschaft für Knochenmark-/Blutstammzelltransplantation
• American Society of Hematology

Aktuellste Veröffentlichungen finden Sie auch unter: Kröger, Nikolaus

1. Donor lymphocyte infusions in amyloid light chain amyloidosis: induction of a "graft-versus-plasma cell dyscrasia effect".
Schonland SO, Kröger N, Wolschke C, Dreger P, Ho AD, Hegenbart U. Haematologica. 2009 Mar; 94(3):439-41.

2. Clinical impact of human Jurkat T-cell-line -derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation.
Ayuk F, Perez-Simon JA, Shimoni A, Sureda A, Zabelina T, Schwerdtfeger R, Martino R, Sayer HG, Alegre A, Lahuerta JJ, Atanackovic D, Wolschke C, Nagler A, Zander AR, San Miguel JF, Kröger N.
Haematologica. 2008 Sep;93(9): 1343-50

3. Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation.
Ayuk F, Diyachenko G, Zabelina T, Wolschke C, Fehse B, Bacher U, Erttmann R, Kröger N, Zander AR.
Biol Blood Marrow Transplantat. 2008 Aug;14(8): 913-9

4. EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT.
Ocheni S, Kroeger N, Zabelina T, Sobottka I, Ayuk F, Wolschke C, Muth A, Lellek H, Petersen L, Erttmann R, Kabisch H, Zander AR, Bacher U.
Bone Marrow Transplantat. 2008 Aug;42(3):181-6.

5. Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors.
Ayuk F, Diyachenko G, Zabelina T, Panse J, Wolschke C, Eiermann T, Binder T, Fehse B, Erttmann R, Kabisch H, Bacher U, Kröger N, Zander AR.
Exp Hematol. 2008 Aug; 36(8): 1047-54.

6. CD4+CD25+FOXP3+T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
Atanackovic D, Cao Y, Luetkens T, Panse J, Faltz C, Arfsten J, Bartels K, Wolschke C, Eiermann T, Zander AR, Fehse B, Bokemeyer C, Kröger N.   
Haematologica. 2008 Mar;93(3): 423-30.

7. Pharmacogenetic analysis of liver toxicity after busulfan/cyclophosphamide -based allogeneic stem cell transplantation.
Goekkurt E, Stoehlmacher J, Stueber C, Wolschke C, Eiermann T, Iacobelli S, Zander AR, Ehninger G, Kröger N.
Anticancer Res. 2007 Nov-Dec; 27(6C): 4377-80.

8. Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukaemia patients after in vivo T-cell depleted unrelated stem cell transplantation.
Kröger N, Binder T, Zabelina T, Wolschke C, Schieder H, Renges H, Ayuk F, Dahlke J, Eiermann T, Zander A.
Transplantation 2006 Oct 27;82(8):1024-30

9. Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation.
Atanakcovic D, Arfsten J, Cao Y, Gnjatic S, Schnieders F, Bartels K, Schilling G, Faltz C, Wolschke C, Dierlamm J, Ritter G, Eiermann T, Hossfeld DK, Zander AR, Jungbluth AA, Old LJ, Bokemeyer C, Kröger N.
Blood 2007 Feb 1; 109(3): 1103-12.

10.Reduced-toxicity conditioning with treosulfan, fludarabin, and ATG preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukaemia (sAML) or myelodysplastic syndrome (MDS).
Kröger N, Shimoni A, Zabelina T, Schieder H, Panse J, Ayuk F, Wolschke C, Renges H, Dahlke J, Atanackovic D, Nagler A, Zander A.
Bone Marrow Transplant. 2006 Feb; 37(4): 339-44.

11. Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)-novel predictors for response and survival in gastric cancer patients.
Goekkurt E, Hoehn S, Wolschke C, Wittmer C, Stueber C, Hossfeld DK, Stoehlmacher J.
Br J Cancer. 2006 Jan 30; 94(2): 281-6.

12. Comparable results in patients with acute lymphoblastic leukaemia after related and unrelated stem cell transplantation.
Dahlke J, Kröger N, Zabelina T, Ayuk F, Fehse N, Wolschke C, Waschke O, Schieder H, Renges H, Krüger W, Kruell A, Hinke A, Erttmann R, Kabisch H, Zander AR.
Bone Marrow Transplant. 2006 Jan; 37(2): 155-63.

13. Pharmacogenetics of extraordinary responses to 5-FU/cisplatin/ chemotherapy in advanced gastric cancer - report of 2 cases.
Wolschke C, Goekkurt E, Al-Batran SE, Hossfeld DK, Stoehlmacher J.
Onkologie. 2005 Nov; 28(11): 589-92.

14. Comparable Results of HLA-Mismatched Vs HLA-Matches Unrelated Donors for Allogeneic Stem Cell Transplantation Using Pre-Transplantat ATG.
Kröger N, Zabelina T, Binder T, Ayuk F, Bacher U, Amtsfeld G, Muth A, Lellek H, Erttmann R, Wolschke C, Eiermann T, Zander AR.
Blood /ASH Annual Meeting Abstracts), Nov. 2008; 112:966

15. Lenalidomide as Salvage Therapy after Allogeneic Stem`Cell Transplantation in 
Multiple Myeloma.
Lehmann F, El-Cheikh J, Zabelina T, Ayuk F, Wolschke C, Atanackovic D, Bacher U, Zander AR, Blaise D, Mothy M, Kröger N.
Blood /ASH Annual Meeting Abstracts), Nov. 2008; 112:3704.

16. Rituximab Plus Donor Lymphocyte Infusion (DLI) to Prevent or Treat Relapse for B Cell Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT).
Cavattoni I, Schieder H, Zabelina T, Bacher U, Ayuk F, Wolschke C, Zander AR, Kröger N.
Blood (ASH Annual Meeting Abstracts), Nov. 2008; 112: 4304.

17. Longitudinal Analysis of Cancer-Testis Antigen Expression in Multiple Myeloma.
Atanackovic D, Luetkens T, Arfsten J, Bartels K, Hildebrandt Y, Cao Y, Faltz C, Wolschke C, Zander AR, Bokemeyer C, Kröger N.
Blood (ASH Annual Meeting Abstracts), Nov 2007; 110: 4826.

18. Lenalidomide after Allogeneic Stem Cell Transplantation in Multiple Myeloma.
Lehmann F, El-Cheikh J, Zabelina T, Ayuk F, Wolschke C, Petersen L, Bacher U, Zander AR, Blaise D, Mothy M, Kröger N.
Blood (ASH Annual Meeting Abstracts), Nov 2007; 110: 4840.

19. Anti-Thymocyte Globulin Induces Higher Response Rates and Less Graft-Versus-Host Disease in Multiple Myeloma Patients Undergoing Allogeneic Stem Cell Transplantation.
Ayuk F, Perez-Simon JA, Shimoni A, Sureda A, Zabelina T, Schwerdtfeger R, Martino R, Sayer HG, Alegre A, Lahuerta JJ, Atanackovic D, Wolschke C, Nagler A; Zander AR, San Miguel J, Kröger N.
Blood (ASH Annual Meeting Abstracts), Nov 2007; 110: 2980.

20. Antifungal Prophylaxis in Allogeneic Stem Cell Transplantation: Results of a Retrospective Cohort Study.
Wolschke C, Lellek H, Heinzelmann M, Kröger N, Zander AR
Blood (ASH Annual Meeting Abstracts), Nov 2007; 110: 5004.

21. Multiple Myeloma Patients Treated with Allogeneic Stem Cell Transplantation Show an Increased Frequency of Bone Marrow Residing CD4+Foxp3+ T Regulatory Cells.
Atanackovic D, Cao Y, Faltz C, Bartels K, Wolschke C, Brummendorf TH, Zander AR, Bokemeyer C, Kröger N.
Blood (ASH Annual Meeting Abstracts), Nov 2006; 108: 5206.

22. Experiences with Caspofungin Plus Posaconazole in Immunocompromised Adults with Invasive Aspergillosis (IA) Refractory to Prior Standard Therapy.
Dahlke J, Zabelina T, Lellek H, Muth A, Waschke O, Wolschke C, Sobottka I, Kröger N, Zander AR.
Blood (ASH Annual Meeting Abstracts), Nov 2006; 108: 5297.

23. Pegfilgastrim after Allogeneic Transplantation -A Alternative to Daily Filgastrim?.
Wolschke C, Zabelina T, Heinzelmann M, Dahlke J, Kröger N, Zander AR
Blood (ASH Annual Meeting Abstracts), Nov 2005; 106: 5306.

24. MTHFR-A1298C Polymorphism Is Associated with Veno-Occlusive Disease (VOD) and Liver Toxicity after Busulfan/Cyclophosphamide Conditioning Followed by Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).
Goekkurt E, Stoehlmacher J, Stueber C, Wolschke C, Zabelina T, Eiermann T, Binder T, Iacobelli S, Zander AR, Kröger N.
Blood (ASH Annual Meeting Abstracts), Nov 2005; 106: 2730.

25. Expression of Cancer/Testis Antigens CT10 and SSX in Multiple Myeloma: Promising Targets for Antgen-Specific Immunotherapy.
Atanackovic D, Arfsten J, Cao Y, Wolschke C, Bartels K, Faltz C, Hossfeld DK, Zander AR, Bokemeyer C, Kröger N.
Blood (ASH Annual Meeting Abstracts), Nov 2005; 106: 3468.

26. Donor KIR Haplotype Genes Significantly Influence Disease-Free and Overall Survival after Myeloablative Conditioning Followed by In Vivo T-Cell Depleted (ATG) Unrelated Stem Cell Transplantation.
Kröger N, Binder T, Schieder H, Renges H, Ayuk F, Wolschke C, Eiermann TH, Zander AR.
Blood (ASH Annual Meeting Abstracts), Nov 2005; 106: 2040.

27. Allogeneic Stem Cell Transplantation from Unrelated Donors within Seventh Decade of Life.
Dahlke J, Zabelina T, Ayuk F, Panse J, Schieder H, Renges H, Atanackovic D, Wolschke C, Zander AR, Kröger N.
Blood (ASH Annual Meeting Abstracts), Nov 2005; 106: 2062.